ASCO 2019: Lichtblicke beim Prostatakarzinom und Pankreaskarzinom, Dämpfer beim Weichteilsarkom
OA Dr. Thamer Sliwa, Hanusch-Krankenhaus Wien, über die Studien der diesjährigen Plenary Session.
Abstracts, die im Video diskutiert werden:
Sweeney C et al. Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial. Abstract LBA2
Tap WD et al. ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS). Abstract LBA3
Kindler HL et al. Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial. Abstract LBA4